Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Company research

Generate Biomedicines, Inc.

CIK 2100782Updated Nov 14, 2026

GENB price & chart

Provider market data

Loading TradingView…

NASDAQ:GENB on TradingView ↗

TradingView · Data may be delayed

About the company

Generate (Nasdaq: GENB) is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, and medicine, advancing a new era of programmable biology to engineer better drug candidates for patients, faster. The Generate Platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address historically undruggable and hard-to-drug targets, as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded in 2018, Generate is leading a fundamental shift from drug discovery to drug generation. Learn more at www.generatebiomedicines.com or follow us on X, LinkedIn, and YouTube.

8-K · 2026-11-12 · 0001193125-26-456921

Company description from the cited filing.

In the news

Seeking Alpha
SEC disclosures

Recent filings

  1. Results of Operations and Financial Condition

    Items 2.02, 9.01

    8-K · 2026-11-12 · 0001193125-26-456921

  2. 10-Q filing

    10-Q · 2026-11-12 · 0001193125-26-456890

  3. SCHEDULE 13G - filed by FMR LLC regarding Generate Biomedicines, Inc.

    SCHEDULE 13G · 2026-11-05 · 0000315066-26-002749

  4. 4 filing

    4 · 2026-11-04 · 0001193125-26-447199

  5. 144 filing

    144 · 2026-10-29 · 0001959173-26-007553

Show 5 more recent filings
  1. Regulation FD Disclosure

    Items 7.01, 9.01

    8-K · 2026-08-26 · 0001193125-26-365556

  2. 10-Q filing

    10-Q · 2026-08-06 · 0001193125-26-336437

  3. Results of Operations and Financial Condition

    Items 2.02, 9.01

    8-K · 2026-08-06 · 0001193125-26-336462

  4. 10-Q filing

    10-Q · 2026-05-07 · 0001193125-26-210059

  5. Results of Operations and Financial Condition

    Items 2.02, 9.01

    8-K · 2026-05-07 · 0001193125-26-209899

Offerings

Registration 333-293204

S-1/A · 2026-02-13 · 0001193125-26-051761

Terms from the governing filing for this registration; not a claim that the offering is open today.

Filing attachments

ck0002100782-ex99_1.htm · 8-K · 2026-11-12

Exhibit 99.1 Generate Biomedicines Reports Third Quarter 2026 Financial Results and Provides Business Update GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year A single dose of GB-0895 produced sustained pharmacological activity for at least six months in COPD Zealand Pharma collaboration provides $30 million upfront, $35 million in early preclinical milestones and nearly $1.2 billion in total potential milestones, plus tiered royalties Anthropic collabo…

8-K · 2026-11-12 · 0001193125-26-456921

Read attachment ↗
ck0002100782-ex99_1.htm · 8-K · 2026-08-26

EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 GB-0895, a next-generation anti-TSLP mAb, demonstrates durable pharmacologic activity supporting a single subcutaneous injection every 6 months for asthma patients. Dave Singh1, Kapil Mayawala2, Victoria Szenes2, Andreas Eich3, Brian Leaker4, Philipp Badorrek5, Stanislav Ignatenko6, Sacha Prashad2, Stephanie Straley2, Antonios Aliprantis7, Lovely Goyal2, Alex Synder2, Oliver Kornmann3 Affiliations: 1University of Manchester, Ma…

8-K · 2026-08-26 · 0001193125-26-365556

Read attachment ↗
ck0002100782-ex99_1.htm · 8-K · 2026-08-06

EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruitment underway across all six global regions Phase 1b data for GB-0895 in COPD to be presented in a poster at the European Respiratory Society (ERS) Congress 2026 on Sept. 8 All patients enrolled in first cohort …

8-K · 2026-08-06 · 0001193125-26-336462

Read attachment ↗
ck0002100782-ex99_1.htm · 8-K · 2026-05-07

EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in mid-2026; program has received FDA Fast Track designation First patient dosing is expected in the second half of 2026 for GB-5267 (M…

8-K · 2026-05-07 · 0001193125-26-209899

Read attachment ↗
ck0002100782-ex4_1.htm · S-1/A · 2026-02-13

Exhibit 4.1 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.001 Generate: Biomedicines Certificate Number ZQ00000000 COMMON STOCK Shares * 000000 **** 000000 ******* ******* 000000 ********* ** 000000 ********* ****** 000000 * Generate Biomedicines, Inc. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT ** Mr. Alexander David Sample SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 370920 10 0 is the owner of **000000**Shares**** ***ZERO HUNDRED THOU…

S-1/A · 2026-02-13 · 0001193125-26-051761

Read attachment ↗
ck0002100782-ex4_3.htm · S-1/A · 2026-02-13

Exhibit 4.3 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (the “Agreement”) is made as of May 9, 2023, by and among Generate Biomedicines, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto (each of which is referred to in this Agreement as an “Investor”, and together with any subsequent investors, or transferees, who become parties hereto as “Investors” pursuant to Subsection 6.9, the “In…

S-1/A · 2026-02-13 · 0001193125-26-051761

Read attachment ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.